Know Labs

Know Labs, Inc. is a publicly traded (NYSE: KNW) medical technology company focused on the development and commercialization of non-invasive diagnostic technologies. Their primary focus is on a platform technology called Bio-Raman Spectroscopy, which they aim to use for continuous, non-invasive blood glucose monitoring.

Know Labs' underlying technology utilizes light to analyze the molecular composition of substances. By directing light through or reflecting light off a substance, and then analyzing the scattered light, they can identify and quantify specific molecules. In the case of glucose monitoring, the aim is to measure glucose levels in the blood without requiring a finger prick or other invasive methods.

The company's work is currently focused on obtaining regulatory approvals, primarily from the U.S. Food and Drug Administration (FDA), for their non-invasive glucose monitoring device. They are conducting clinical trials to validate the accuracy and reliability of their technology.

The potential benefits of non-invasive glucose monitoring include improved convenience for individuals with diabetes, more frequent monitoring, and reduced risk of infection compared to traditional methods. However, the technology is still under development and has not yet received regulatory clearance for commercial use.

Know Labs is headquartered in Seattle, Washington. Their executive team is composed of individuals with experience in medical device development, regulatory affairs, and commercialization.

The information provided herein is for informational purposes only and does not constitute medical advice. It is essential to consult with qualified healthcare professionals for any health concerns or before making any decisions related to your health or treatment.